Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective
Basic & Clinical Pharmacology & Toxicology · 2025-03 · 136 (3)
DOI: 10.1111/bcpt.70009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 19.02.2025. Verfasst von Niels Westergaard und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Nursing, University College Absalon, Roskilde, Denmark. Hauptthemen laut MEDLINE: Precision Medicine, Pharmacogenomic Testing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Precision medicine has significantly advanced through the development of predictive biomarkers based on pharmacogenetic (PGx) testing. These tests identify interactions between drugs and genetic variants that influence patient responses to treatments. Understanding genetic variations in drug‐metabolizing enzymes, receptors and transporters and their impact on pharmacokinetics and pharmacodynamics allows for the prediction of drug effects and side effects, enabling tailored treatments for different patient groups. This review focuses on drugs metabolized by cytochrome P450 (CYP450) enzymes, for example, citalopram and clopidogrel or transported by the solute carrier organic anion transporter family member 1B1 (SLCO1B1), for example, atorvastatin and simvastatin, with PGx dosing guidelines, in the context of consumption in Scandinavian countries. A major barrier to the widespread adoption of PGx tests in clinical practice has been healthcare professionals' uncertainty about their efficacy, complexity in result interpretation and questions regarding the evidence base. However, recent studies have demonstrated PGx testing has the potential to improve treatment outcomes, reduce adverse drug reactions and achieve cost savings. These findings underscore the potential of PGx testing as a valuable tool in clinical decision making, promoting its use in a pre‐emptive manner to enhance patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Nursing, University College Absalon, Roskilde, Denmark.
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Copenhagen, Denmark.
- Hospital Pharmacy Capital Region of Denmark, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
ORCID-Profile: Niels Westergaard, Trine Meldgaard Lund, Charlotte Vermehren
Zitieren
APA
Westergaard, N., Lund, T. M., & Vermehren, C. (2025). Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective. Basic & Clinical Pharmacology & Toxicology, 136(3). https://doi.org/10.1111/bcpt.70009
Vancouver
Westergaard N, Lund TM, Vermehren C. Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective. Basic & Clinical Pharmacology & Toxicology. 2025;136(3). doi:10.1111/bcpt.70009
BibTeX
@article{Westergaard2025,
author = {Westergaard, Niels and Lund, Trine Meldgaard and Vermehren, Charlotte},
title = {Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
volume = {136},
number = {3},
doi = {10.1111/bcpt.70009}
}
EUVIMED